Test Price
700 AED✅ Home Collection Available
Inv(16) (CBFB-MYH11) FISH Test for AML M4Eo in UAE | 700 AED | DHA Approved
Executive Summary & Core Metrics
This highly precise fluorescence in-situ hybridization (FISH) assay detects the inversion 16 / CBFB-MYH11 gene rearrangement, the molecular hallmark of acute myeloid leukemia with eosinophilia (AML M4Eo). With a diagnostic sensitivity exceeding 99.9%, this ISO-accredited test provides the genetic confirmation necessary for risk-stratified therapy and prognostic evaluation.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Processing.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for comprehensive result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Inv(16) FISH test utilizes a dual-color, break-apart probe strategy targeting the CBFB gene locus at 16q22. This highly sensitive technique can detect the classic inv(16)(p13.1q22) as well as variant translocations, such as t(16;16)(p13.1;q22), which are pathognomonic for AML M4Eo. Identifying this rearrangement is clinically critical, as it confers a favorable prognosis and informs the use of high-dose cytarabine-based regimens. Detection is performed on interphase nuclei from bone marrow aspirate or peripheral blood, bypassing the need for metaphase cells required by conventional karyotyping.
| Parameter | Our Test (FISH) | Conventional Karyotyping |
|---|---|---|
| Precision | Detects 100% of inv(16)/t(16;16) with CBFB break-apart probe, even in cryptic rearrangements | Detects ~90% of inv(16) if metaphase quality is good; may miss cryptic cases |
| Method | Fluorescence In-Situ Hybridization (FISH) on interphase nuclei | G-banded chromosome analysis requiring dividing cells |
| Turnaround Time | 3–4 days | 7–14 days |
| Sample | Bone Marrow / Peripheral Blood | Bone Marrow only (requires viable metaphases) |
Physician Insight & Safety Protocols
“As a specialist in diagnostic radiology and oncological pathology, I emphasize that the detection of inv(16) via FISH is a cornerstone of risk-stratified AML management. A positive result must be integrated with full clinical, morphological, and immunophenotypic data to confirm M4Eo and guide tailored therapeutic strategies.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication & Test Utilization Advisory
This genetic diagnostic tool is designed to inform clinical decision-making and must never be used as a substitute for professional medical judgment or as a reason to alter prescribed treatment regimens. Patients are strictly advised to maintain their prescribed medications unless explicitly directed otherwise by their managing hematologist or oncologist. Any clinical trial or treatment protocol adjustments should be made only by the supervising physician.
Exclusion Criteria & Emergency Red Flags
- This test is strictly indicated for patients with a strong clinical suspicion of acute myeloid leukemia (e.g., unexplained cytopenias, circulating blasts, persistent eosinophilia).
- It is not intended for routine wellness screening and requires a valid physician's prescription.
- Emergency Red Flags: Sudden onset of high fever, uncontrolled or unexplained bleeding, profound fatigue, or new neurological symptoms warrant immediate emergency department evaluation.
Patient FAQ & Clinical Guidance
1. What specific genetic abnormality does the Inv(16) FISH test detect?
This test precisely identifies the inversion of chromosome 16, specifically the CBFB-MYH11 gene fusion, which is the definitive molecular marker for AML M4Eo. Detecting this abnormality is essential for confirming the diagnosis, determining prognosis, and selecting the most effective targeted chemotherapy protocols.
2. Why is a bone marrow biopsy necessary for this test, and can I opt for a blood test instead?
While the CBFB-MYH11 rearrangement can be detected in peripheral blood, the gold standard sample is a bone marrow aspirate to accurately quantify the blast percentage and confirm the diagnosis. Per our strict safety protocols, bone marrow collection requires a hospital extraction and cannot be performed via mobile phlebotomy.
3. How are the results of this FISH test used in my overall cancer treatment plan?
A positive inv(16) result stratifies AML into the favorable-risk category. This directly influences your oncologist's decision to utilize high-dose cytarabine (HiDAC) regimens and can guide discussions about allogeneic stem cell transplantation in refractory cases. A detailed post-test clinical guidance session is provided to discuss the implications of your result.
4. What is the turnaround time for the Inv(16) FISH test in the UAE?
The standard processing time is 3 to 4 business days. Results are delivered electronically to your referring physician and discussed with you during a scheduled telephonic clinical guidance session.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the UAE's highest data privacy and healthcare regulatory standards. All patient data and genetic information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility (License No. 1143) ensures that all diagnostic procedures meet the stringent quality benchmarks required for oncological genetic testing.
Clinical & Logistical Metadata
| Test Name | Inv(16) (CBFB-MYH11) FISH for AML M4Eo |
| Price (AED) | 700 |
| Turnaround Time | 3 to 4 Business Days |
| Sample Type / Matrix | Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. (Bone Marrow / Peripheral Blood) |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) – Dual-Color Break-Apart Probe |
| ICD-10-CM Code | C92.5 |
| LOINC Code | 60506-6 |
| DHA Facility License & Laboratory Address | 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians